Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide is an investigational triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors. This unique mechanism helps reduce appetite, improve insulin sensitivity, and increase energy expenditure, making it one of the most potent weight-loss and metabolic health compounds currently under investigation. Clinical trials have demonstrated significant reductions in body weight along with improvements in glycemic control and cardiometabolic markers.
Common Research Dosing Protocol:
Week 1-4: 2 mg once weekly
Week 5-8: 4 mg once weekly
Week 9-12: 6 mg once weekly
Week 13+: Increase by 2-4 mg increments every 4 weeks as tolerated
Typical effective range: 4-12 mg once weekly
Maximum dose studied in clinical trials: 12 mg once weekly
Administration:
Subcutaneous injection
Administer on the same day each week
Rotate injection sites between abdomen, thigh, and upper arm
Storage:
Refrigerate at 36-46°F (2-8°C)
Protect from light
Do not freeze
Use within the supplier's recommended period after reconstitution
Notes:
Gradual dose escalation is recommended to minimize gastrointestinal side effects such as nausea, vomiting, constipation, and diarrhea. Many users find that remaining at a dose level for longer than 4 weeks improves tolerability while still providing substantial benefits. Retatrutide remains an investigational compound and has not yet received FDA approval.
Retatrutide is an investigational triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors. This unique mechanism helps reduce appetite, improve insulin sensitivity, and increase energy expenditure, making it one of the most potent weight-loss and metabolic health compounds currently under investigation. Clinical trials have demonstrated significant reductions in body weight along with improvements in glycemic control and cardiometabolic markers.
Common Research Dosing Protocol:
Week 1-4: 2 mg once weekly
Week 5-8: 4 mg once weekly
Week 9-12: 6 mg once weekly
Week 13+: Increase by 2-4 mg increments every 4 weeks as tolerated
Typical effective range: 4-12 mg once weekly
Maximum dose studied in clinical trials: 12 mg once weekly
Administration:
Subcutaneous injection
Administer on the same day each week
Rotate injection sites between abdomen, thigh, and upper arm
Storage:
Refrigerate at 36-46°F (2-8°C)
Protect from light
Do not freeze
Use within the supplier's recommended period after reconstitution
Notes:
Gradual dose escalation is recommended to minimize gastrointestinal side effects such as nausea, vomiting, constipation, and diarrhea. Many users find that remaining at a dose level for longer than 4 weeks improves tolerability while still providing substantial benefits. Retatrutide remains an investigational compound and has not yet received FDA approval.